Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis
US9523691B2 · kind B2 · utility
0Cited by
0References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 2, 2011 |
| Grant date | Dec 20, 2016 |
| Priority date | — |
| Expiry date | Mar 2, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2001/284
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method for diagnosing KRAS mutations in colorectal cancers by measuring the level of OLFM4. In another aspect, the present invention relates a method of predicting the responds to a chemotherapeutic agent of a subject suffering from a colorectal cancer: according to the present invention, the by determining the OLFM4 levels. According to the present invention, the response can be predicted by determining the OLFM4 levels. This result in turn permits the design or the adaptation of a treatment of the said subject with the said chemotherapeutic agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.